Examination of Epigenetic Inhibitor Zebularine in Treatment of Skin Wounds in Healthy and Diabetic Mice

The study examined the effects of the epigenetic inhibitor zebularine on skin wound healing in both healthy and diabetic mice. Zebularine, administered either intraperitoneally or topically, did not significantly enhance wound healing in most cases. In diabetic mice, zebularine treatment even resulted in a significant delay in wound closure. While zebularine showed minimal toxicity in fibroblasts, it inhibited keratinocyte viability, especially in diabetic patients. Although zebularine did not markedly improve wound healing, it influenced tissue architecture and gene expression related to skin regeneration, suggesting potential for anti-scarring applications. The study emphasized the need for dose optimization and suggested exploring other DNA demethylating agents with better stability and lower toxicity for wound treatment.